Sonnet BioTherapeutic News

Sonnet BioTherapeutics Analyst Ratings

BenzingaFeb 16 01:33

BTIG Reaffirms Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)

TipRanksJan 7 18:47

Sonnet BioTherapeutics Holdings (SONN) Gets a Buy From BTIG

TipRanksJan 2 22:49

Ladenburg Thalmann Initiates Coverage On Sonnet BioTherapeutics With Buy Rating, Announces Price Target of $7

BenzingaNov 27, 2023 22:00

Sonnet BioTherapeutics Analyst Ratings

BenzingaNov 27, 2023 21:59

Sonnet BioTherapeutics Analyst Ratings

BenzingaAug 23, 2023 16:36

Sonnet BioTherapeutics Analyst Ratings

BenzingaAug 16, 2023 22:22

Chardan Capital Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)

TipRanksAug 16, 2023 21:35

Chardan Cuts Price Target on Sonnet BioTherapeutics to $12 From $14, Keeps Buy Rating

MT NewswiresAug 16, 2023 21:32

Sonnet BioTherapeutics Holdings (SONN) Receives a Buy From EF Hutton

TipRanksJun 27, 2023 00:25

Chardan Lowers Price Target on Sonnet BioTherapeutics to $14 From $17, Keeps Buy Rating

MT NewswiresMay 11, 2023 18:23

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $14

BenzingaMay 11, 2023 17:21

Chardan Cuts Price Target on Sonnet BioTherapeutics to $17 From $22, Anticipating Higher Future Share Count, Maintains Buy Rating

MT NewswiresApr 19, 2023 19:23

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $17

BenzingaApr 19, 2023 18:25

EF Hutton Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)

TipRanksFeb 15, 2023 20:35

Sonnet BioTherapeutics Analyst Ratings

Benzinga Analyst RatingsFeb 15, 2023 17:41

EF Hutton Reiterates Buy on Sonnet BioTherapeutics, Maintains $6.7 Price Target

Benzinga Real-time NewsFeb 15, 2023 17:41

Sonnet BioTherapeutics Analyst Ratings

Benzinga Analyst RatingsDec 19, 2022 20:11